Replies to post #124909 on Biotech Values

[pcrutch]

speaking of which, $FOLD looks unduly beaten up at $4.47($150M mcap). I mean, $GSK invested in $FOLD at $4.56 per share back on October 29, 2010.

$FOLD 2Q Results - http://t.co/nv0v1u4
- current cash of $83 million
- Phase 2 (Study 013) preliminary results of Amigal co-administered with enzyme replacement therapy (ERT) on track for 4Q11(for Fabry's disease)

[jq1234]

Quite possible, so few player in this space. First time a subcutaneous enzyme replacement therapy.